NASDAQ:BNTX BioNTech (BNTX) Stock Forecast, Price & News $101.86 -1.26 (-1.22%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$101.09▼$102.6450-Day Range$98.50▼$125.0852-Week Range$95.50▼$188.99Volume419,068 shsAverage Volume683,853 shsMarket Capitalization$24.55 billionP/E Ratio5.71Dividend YieldN/APrice Target$158.69 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioNTech MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside55.8% Upside$158.69 Price TargetShort InterestHealthy1.01% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth-64.05%From $6.62 to $2.38 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 starsMedical Sector434th out of 964 stocksBiological Products, Except Diagnostic Industry61st out of 157 stocks 3.3 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $158.69, BioNTech has a forecasted upside of 55.8% from its current price of $101.86.Amount of Analyst CoverageBioNTech has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.01% of the outstanding shares of BioNTech have been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNTech has recently increased by 15.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 3.3 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for BioNTech this week, compared to 6 articles on an average week.Search Interest33 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 32% compared to the previous 30 days.MarketBeat Follows13 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is an increase of 63% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to decrease by -64.05% in the coming year, from $6.62 to $2.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 5.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.06.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 5.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 153.33.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioNTech (NASDAQ:BNTX) StockBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More BNTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Stock News HeadlinesSeptember 7, 2023 | marketbeat.com3 Stocks to Buy For the COVID Resurgence (BNTX)The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be votingSeptember 23, 2023 | finance.yahoo.comBioNTech SE's (NASDAQ:BNTX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?September 27, 2023 | Behind the Markets (Ad)AI Creates New Cancer Drug - In Just 30 Days!On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...September 23, 2023 | msn.comBioNTech Is Revising Plans for African Vaccine Factory NetworkSeptember 19, 2023 | ca.news.yahoo.comBioNTech wins up to $90 million in funding for mpox vaccine developmentSeptember 18, 2023 | news.yahoo.comBioNTech partners with CEPI to advance development of mpox vaccineSeptember 18, 2023 | benzinga.comBioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI's 100 Days MissionSeptember 18, 2023 | markets.businessinsider.comBioNTech To Initiate Phase 1/2 Clinical Trial Of MRNA-based Mpox Vaccine Program BNT166September 27, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.September 15, 2023 | markets.businessinsider.comMore Than Half Of Americans Want New COVID-19 Booster, But Ron DeSantis Will Fight Virus With His Charisma AloneSeptember 13, 2023 | msn.comBioNTech: Renewed COVID Focus Might Spark Potential Share Price BoostSeptember 12, 2023 | msn.comCDC recommends COVID-19 shots for people age six months and older (update)September 11, 2023 | marketwatch.comPfizer, BioNTech Get FDA OK for Updated Covid-19 Vaccine >PFE BNTXSeptember 7, 2023 | msn.comMHRA grants approval for Pfizer-BioNTech’s adapted vaccine for Covid-19September 6, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Moderna (MRNA), Dexcom (DXCM) and BioNTech SE (BNTX)September 5, 2023 | finance.yahoo.comCancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The BattleSeptember 1, 2023 | msn.comEurope Approves Pfizer/BioNTech's Adapted COVID-19 Vaccine For Upcoming Autumn Vaccination CampaignsSeptember 1, 2023 | theglobeandmail.comEU authorizes use of adapted Pfizer/BioNtech vaccine for COVID-19 variantAugust 30, 2023 | finanznachrichten.deBioNTech SE: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European UnionAugust 30, 2023 | benzinga.comBioNTech Unusual Options Activity For August 30August 30, 2023 | markets.businessinsider.comPfizer, BioNTech Obtain Positive CHMP Opinion For Omicron XBB.1.5-adapted COVID-19 Vaccine In EUAugust 30, 2023 | finance.yahoo.comInsiders own 20% of BioNTech SE (NASDAQ:BNTX) shares but private equity firms control 44% of the companyAugust 30, 2023 | finance.yahoo.comPfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European UnionAugust 28, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on BioNTech SE (BNTX)August 28, 2023 | benzinga.comWhy BioNTech Shares Are Rising During Monday's SessionAugust 22, 2023 | baystreet.caHow to Play the Covid Vaccine RallyAugust 22, 2023 | msn.comVaccine makers light up as COVID hospitalizations riseSee More Headlines Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Email Address BNTX Company Calendar Last Earnings8/07/2023Today9/27/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees4,530Year Founded2008Price Target and Rating Average Stock Price Forecast$158.69 High Stock Price Forecast$260.00 Low Stock Price Forecast$116.00 Forecasted Upside/Downside+55.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$17.84 Trailing P/E Ratio5.71 Forward P/E Ratio15.39 P/E GrowthN/ANet Income$9.94 billion Net Margins47.37% Pretax Margin62.27% Return on Equity21.46% Return on Assets18.71% Debt Debt-to-Equity Ratio0.01 Current Ratio10.56 Quick Ratio10.32 Sales & Book Value Annual Sales$18.24 billion Price / Sales1.35 Cash Flow$40.42 per share Price / Cash Flow2.52 Book Value$87.07 per share Price / Book1.17Miscellaneous Outstanding Shares240,990,000Free Float194,720,000Market Cap$24.55 billion OptionableNot Optionable Beta0.17 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesProf. Ugur Sahin M.D. (Age 58)Co-Founder, CEO & Chair of the Management Board Comp: $479.34kDr. Ozlem Tureci M.D. (Age 56)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $890.97kMr. Jens H. Holstein (Age 60)CFO & Member of Management Board Comp: $938.26kDr. Sierk Poetting Ph.D. (Age 50)MD, COO & Member of Management Board Comp: $985.54kMr. Ryan Richardson (Age 44)Chief Strategy Officer, MD & Member of Management Board Comp: $476.11kMr. Sean Marett (Age 58)Chief Bus. Officer, Chief Commercial Officer & Member of Management Board Comp: $913.54kDr. James Timothy Patrick Ryan Ph.D. (Age 48)Chief Legal Officer & Member of the Management Board Sylke Maas Ph.D.VP of Investor Relations and Bus. StrategyMichael BoehlerMD & Head of Global External CommunicationsDr. Oliver Hennig Ph.D.Sr. VP of OperationsMore ExecutivesKey CompetitorsargenxNASDAQ:ARGXModernaNASDAQ:MRNABiogenNASDAQ:BIIBNeurocrine BiosciencesNASDAQ:NBIXBio-TechneNASDAQ:TECHView All CompetitorsInstitutional OwnershipBarclays PLCSold 42,932 shares on 9/21/2023Ownership: 0.030%Wolverine Trading LLCBought 23,800 shares on 8/23/2023Ownership: 0.000%Osaic Holdings Inc.Sold 906 shares on 8/21/2023Ownership: 0.003%GTS Securities LLCBought 58,453 shares on 8/16/2023Ownership: 0.024%Captrust Financial AdvisorsBought 172 shares on 8/15/2023Ownership: 0.002%View All Institutional Transactions BNTX Stock - Frequently Asked Questions Should I buy or sell BioNTech stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BNTX shares. View BNTX analyst ratings or view top-rated stocks. What is BioNTech's stock price forecast for 2023? 10 equities research analysts have issued 12-month price targets for BioNTech's stock. Their BNTX share price forecasts range from $116.00 to $260.00. On average, they expect the company's share price to reach $158.69 in the next year. This suggests a possible upside of 55.8% from the stock's current price. View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts. How have BNTX shares performed in 2023? BioNTech's stock was trading at $150.22 at the start of the year. Since then, BNTX shares have decreased by 32.2% and is now trading at $101.86. View the best growth stocks for 2023 here. When is BioNTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our BNTX earnings forecast. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.04. The business earned $167.70 million during the quarter, compared to analyst estimates of $628.13 million. BioNTech had a net margin of 47.37% and a trailing twelve-month return on equity of 21.46%. BioNTech's quarterly revenue was down 94.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $7.31 earnings per share. What ETFs hold BioNTech's stock? ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and iShares Biotechnology ETF (IBB). What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD). When did BioNTech IPO? (BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. What is BioNTech's stock symbol? BioNTech trades on the NASDAQ under the ticker symbol "BNTX." Who are BioNTech's major shareholders? BioNTech's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.09%), Temasek Holdings Private Ltd (1.88%), Flossbach Von Storch AG (1.43%), Artisan Partners Limited Partnership (0.84%), BlackRock Inc. (0.72%) and Capital World Investors (0.38%). How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioNTech's stock price today? One share of BNTX stock can currently be purchased for approximately $101.86. How much money does BioNTech make? BioNTech (NASDAQ:BNTX) has a market capitalization of $24.55 billion and generates $18.24 billion in revenue each year. The company earns $9.94 billion in net income (profit) each year or $17.84 on an earnings per share basis. How many employees does BioNTech have? The company employs 4,530 workers across the globe. Does BioNTech have any subsidiaries? The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.Read More How can I contact BioNTech? BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The official website for the company is www.biontech.de. The company can be reached via phone at 49-61-31908-40, via email at investors@biontech.de, or via fax at 49-6131-908-4390. This page (NASDAQ:BNTX) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.